Mandate

Vinge has advised Bilia AB publ

Vinge has advised Bilia AB (publ), listed on NASDAQ Stockholm, in conjunction with a tap issue of MSEK 250 within the scope of its non-subordinated corporate bonds, with a maturity date in March 2021.

The issue was performed as an interest expense corresponding to STIBOR 3 months + 150 interest points up to maturity. In total, the new outstanding amount following the issue is MSEK 750.

Vinge’s team consisted of responsible advokat Yohanna Öhrnegård assisted by Lina André.

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026